Literature DB >> 7658155

Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression.

M C Lin1, D Gordon, J R Wetterau.   

Abstract

The microsomal triglyceride transfer protein (MTP) is a heterodimeric lipid transfer protein that is required for the assembly and secretion of apoB-containing lipoproteins. In this study, four factors that modulate lipid and lipoprotein metabolism were tested for their ability to regulate MTP levels in HepG2 cells. Of the factors tested, only insulin (> or = 10(-9) M), and high concentrations of glucose (> 30 mM) were found to decrease MTP large subunit mRNA levels. Oleate and glucagon had no effect on MTP mRNA levels. The insulin effect was dose- and time-dependent and was mediated through the insulin receptor. In addition, insulin also decreased protein disulfide isomerase (the small subunit of MTP) mRNA levels, although to a lesser extent. Due to the slow turnover rate of MTP (t1/2 = 4.4 days), short-term insulin treatment (24 h) did not change MTP activity levels, indicating that the regulation of MTP mRNA levels by insulin is unrelated to insulin's acute inhibition of apoB secretion in HepG2 cells. In summary, MTP mRNA levels are acutely regulated by insulin in HepG2 cells; however, sustained changes in MTP mRNA levels would be required to affect MTP protein levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658155

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  41 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Hepatic regulation of apolipoprotein B.

Authors:  Rita Kohen Avramoglu; Khosrow Adeli
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

3.  Acute suppression of apo B secretion by insulin occurs independently of MTP.

Authors:  Janet D Sparks; Jeffrey M Chamberlain; Colleen O'Dell; Irani Khatun; M Mahmood Hussain; Charles E Sparks
Journal:  Biochem Biophys Res Commun       Date:  2011-02-18       Impact factor: 3.575

Review 4.  Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Authors:  Sung Hee Choi; Henry N Ginsberg
Journal:  Trends Endocrinol Metab       Date:  2011-05-26       Impact factor: 12.015

5.  SHP-2 and PI3-kinase genes PTPN11 and PIK3R1 may influence serum apoB and LDL cholesterol levels in normal women.

Authors:  Y Jamshidi; S B Gooljar; H Snieder; X Wang; D Ge; R Swaminathan; T D Spector; S D O'Dell
Journal:  Atherosclerosis       Date:  2007-01-09       Impact factor: 5.162

6.  Decreased secretion of very-low-density lipoprotein triacylglycerol and apolipoprotein B is associated with decreased intracellular triacylglycerol lipolysis in hepatocytes derived from rats fed orotic acid or n-3 fatty acids.

Authors:  A M Hebbachi; M C Seelaender; B W Baker; G F Gibbons
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

7.  An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells.

Authors:  H Jamil; D A Gordon; D C Eustice; C M Brooks; J K Dickson; Y Chen; B Ricci; C H Chu; T W Harrity; C P Ciosek; S A Biller; R E Gregg; J R Wetterau
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 8.  Dynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise training.

Authors:  Jean-Marc Lavoie
Journal:  World J Hepatol       Date:  2016-08-18

9.  CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression.

Authors:  Stefanie Y Tan; Hannah C Little; Dylan C Sarver; Paul A Watkins; G William Wong
Journal:  FEBS Lett       Date:  2020-08-14       Impact factor: 4.124

Review 10.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.